Tianshili (600535.SH): Glucosamine sulfate capsules obtained drug registration certificate

Zhitongcaijing · 06/10 07:57

Zhitong Finance App News, Tasly (600535.SH) issued an announcement. Recently, Tianjin Tianshili Shengte Pharmaceutical Co., Ltd. (“Tianshili Shengte”), a wholly-owned subsidiary of the company, received a “Drug Registration Certificate” for glucosamine sulfate capsules issued by the State Drug Administration.

It is reported that glucosamine sulfate capsules are suitable for primary and secondary osteoarthritis. The original glucosamine sulfate capsule research drug was approved for marketing in Italy in 1982. The licensee is ROTAPHARMS.P.A., the trade name is Viartril-S, and it was approved for sale in China in 1996. In 2018, the State Drug Administration changed the drug from prescription drugs to non-prescription drugs in accordance with the provisions of the “Administrative Measures on Classification of Prescription Drugs and Non-prescription Drugs (Trial)”.